Dong-A Socio Holdings will absorb its wholly-owned subsidiary, Dong-A Pharmaceutical, transitioning to a holding company structure.
On July 23, Dong-A Socio Holdings announced that its board of directors has resolved to proceed with the merger, which is set to take place on October 1. The merger will be conducted as a small-scale absorption without issuing new shares, and there will be no changes to the existing shareholder composition or ownership ratios.
This decision is seen as a strategic move to shift to a structure that balances business operations and investments, building on over a decade of achievements since the introduction of the holding company system. Since transitioning to a holding company in 2013, Dong-A Socio Holdings has focused on enhancing the expertise of its subsidiaries. Dong-A Pharmaceutical has established a stable revenue base in over-the-counter drugs, healthcare, and dermocosmetics, primarily centered around its flagship product, Bacchus.
The company stated, "In light of intensifying competition in the global and domestic healthcare markets, we have decided to transition to a holding company structure to internalize the cash-generating capabilities of our core subsidiary, Dong-A Pharmaceutical, and to strengthen our group-wide investment and new business development capabilities."
Changes in governance are also anticipated. Dong-A Socio Holdings plans to centralize decision-making authority within its board and management to establish a more agile and accountable management system.
Additionally, the merger is expected to alleviate concerns over dual listings, potentially reducing the so-called 'holding company discount' and leading to a reassessment of corporate value.
The integrated entity plans to accelerate its overseas market penetration based on Dong-A Pharmaceutical's brand competitiveness and distribution infrastructure. The strategy includes expanding e-commerce channels, entering global retail chains, and pursuing brand collaborations to increase the share of overseas sales and elevate its status as a global consumer healthcare company.
A representative from Dong-A Socio Holdings remarked, "This merger is a decision aimed at enhancing our competitiveness in the global healthcare market while inheriting the achievements made since the transition to a holding company. We will leverage our integrated resources to expand investments in new growth drivers, thereby increasing corporate and shareholder value."
Meanwhile, Dong-A Socio Holdings has been recognized as one of the 'ESG Best Companies' for three consecutive years by Sustainalytics in its 2026 mid-year ESG comprehensive evaluation, which assesses the environmental, social, and governance (ESG) management levels of domestic companies twice a year. Dong-A Socio Holdings, Dong-A ST, and ST Pharm have been acknowledged for their sustainable management achievements since their first selection in 2024.
On July 23, Dong-A Socio Holdings announced that its board of directors has resolved to proceed with the merger, which is set to take place on October 1. The merger will be conducted as a small-scale absorption without issuing new shares, and there will be no changes to the existing shareholder composition or ownership ratios.
This decision is seen as a strategic move to shift to a structure that balances business operations and investments, building on over a decade of achievements since the introduction of the holding company system. Since transitioning to a holding company in 2013, Dong-A Socio Holdings has focused on enhancing the expertise of its subsidiaries. Dong-A Pharmaceutical has established a stable revenue base in over-the-counter drugs, healthcare, and dermocosmetics, primarily centered around its flagship product, Bacchus.
The company stated, "In light of intensifying competition in the global and domestic healthcare markets, we have decided to transition to a holding company structure to internalize the cash-generating capabilities of our core subsidiary, Dong-A Pharmaceutical, and to strengthen our group-wide investment and new business development capabilities."
Changes in governance are also anticipated. Dong-A Socio Holdings plans to centralize decision-making authority within its board and management to establish a more agile and accountable management system.
Additionally, the merger is expected to alleviate concerns over dual listings, potentially reducing the so-called 'holding company discount' and leading to a reassessment of corporate value.
The integrated entity plans to accelerate its overseas market penetration based on Dong-A Pharmaceutical's brand competitiveness and distribution infrastructure. The strategy includes expanding e-commerce channels, entering global retail chains, and pursuing brand collaborations to increase the share of overseas sales and elevate its status as a global consumer healthcare company.
A representative from Dong-A Socio Holdings remarked, "This merger is a decision aimed at enhancing our competitiveness in the global healthcare market while inheriting the achievements made since the transition to a holding company. We will leverage our integrated resources to expand investments in new growth drivers, thereby increasing corporate and shareholder value."
Meanwhile, Dong-A Socio Holdings has been recognized as one of the 'ESG Best Companies' for three consecutive years by Sustainalytics in its 2026 mid-year ESG comprehensive evaluation, which assesses the environmental, social, and governance (ESG) management levels of domestic companies twice a year. Dong-A Socio Holdings, Dong-A ST, and ST Pharm have been acknowledged for their sustainable management achievements since their first selection in 2024.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.